Vaccine

BioCT to Host Virtual Panel of Connecticut Companies Working on COVID-19

Vaccination, Vaccine, Virology
Monday, April 6, 2020 - 8:00pm

NEW HAVEN, Conn., April 6, 2020 /PRNewswire-PRWeb/ --WHAT: Connecticut companies that are working on COVID-19 will participate in a virtual (online) panel discussion, open to the public, on the current state of therapeutic and vaccine pipelines, new developments and future plans.

Key Points: 
  • NEW HAVEN, Conn., April 6, 2020 /PRNewswire-PRWeb/ --WHAT: Connecticut companies that are working on COVID-19 will participate in a virtual (online) panel discussion, open to the public, on the current state of therapeutic and vaccine pipelines, new developments and future plans.
  • The panel is presented by BioCT and hosted by AdvanceCT .
  • "As the world eagerly awaits a vaccine to COVID-19, we greatly appreciate the efforts of our Connecticut bioscience companies to develop a solution," Dawn Hocevar, BioCT president and CEO, said.
  • "We look forward to hearing their insights during this discussion."

OncoSec Collaborates with Providence Cancer Institute to Conduct First-in-Human Trial of OncoSec's CORVax12, an Investigational Vaccine to Prevent COVID-19, Combining an Enhanced "Spike" DNA Sequence and TAVO™

Medical specialties, Immunology, Medicine, Branches of biology, Electroporation, Humoral immunity, Vaccine, Immune response, Immunity, Cell-mediated immunity, Immunologic adjuvant
Monday, April 6, 2020 - 2:00pm

CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms.

Key Points: 
  • CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate, adaptive humoral, and adaptive cellular arms.
  • We believe this multi-pronged innate, adaptive and cellular immune response is likely to be important in generating a robust anti-viral response.
  • Importantly, we believe the delivery of CORVax12 using OncoSec's electroporation system may allow for highly effective DNA transfer to drive this investigational vaccine."
  • Dr. Leidner continued, "Providence is among the U.S.'s largest, not-for-profit network of hospitals and includes 51 hospitals in Alaska, Washington, Oregon, Montana and California.

Three Long-Time Emmes Employees Are Named VPs

Vaccination, Vaccine, Virology
Monday, April 6, 2020 - 1:30pm

According to Dr. Anne Lindblad, president and chief executive officer, "These promotions reflect their talent and value to the organization.

Key Points: 
  • According to Dr. Anne Lindblad, president and chief executive officer, "These promotions reflect their talent and value to the organization.
  • Here, Emmes is responsible for the statistical and data coordination of more than 100 vaccine and infectious disease protocols.
  • During her tenure at Emmes, Hill has co-authored more than 50 papers that have been published in a number of scientific journals.
  • Dr. Shah started at Emmes in 2005 as a safety/medical monitor before assuming leadership roles in ophthalmology, autoimmune and inflammation projects.

Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19

Vaccination, Vaccine, Virology
Monday, April 6, 2020 - 2:25pm

Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, commented, We are pleased with the successful completion of this phase in the development of our novel vaccine candidate.

Key Points: 
  • Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, commented, We are pleased with the successful completion of this phase in the development of our novel vaccine candidate.
  • We believe that our ability to clone all three of these antigens will differentiate our vaccine candidate from others.
  • Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.
  • Further information is available on the Companys website: www.premasbiotech.com
    Akers Biosciences is pursuing the development of a newly acquired license to a coronavirus vaccine candidate.

What is the Market Forecast for the Drugs in Development for COVID-19

Viruses, Microbiology, Zoonoses, Vaccination, Vaccine, Virology, Coronavirus, Middle East respiratory syndrome-related coronavirus
Monday, April 6, 2020 - 10:00am

We may not be able to develop a vaccine, but we can try and help the companies that do.

Key Points: 
  • We may not be able to develop a vaccine, but we can try and help the companies that do.
  • So please register NOW to receive your FREE, business information guide to the current and future market of vaccines being designed for COVID-19.
  • Much opportunity remains in this growing Novel Coronavirus (COVID-19) Drugs in Development Market.
  • Along with revenue prediction for the overall world market, there are 2 segmentations of the Novel Coronavirus (COVID-19) Drugs in Development market, with forecasts for 5 Drugs, 5 Age Groups, each forecasted at a global and regional level.

What is the Market Forecast for the Drugs in Development for COVID-19

Viruses, Microbiology, Zoonoses, Vaccination, Vaccine, Virology, Coronavirus, Middle East respiratory syndrome-related coronavirus
Monday, April 6, 2020 - 10:00am

We may not be able to develop a vaccine, but we can try and help the companies that do.

Key Points: 
  • We may not be able to develop a vaccine, but we can try and help the companies that do.
  • So please register NOW to receive your FREE, business information guide to the current and future market of vaccines being designed for COVID-19.
  • Much opportunity remains in this growing Novel Coronavirus (COVID-19) Drugs in Development Market.
  • Along with revenue prediction for the overall world market, there are 2 segmentations of the Novel Coronavirus (COVID-19) Drugs in Development market, with forecasts for 5 Drugs, 5 Age Groups, each forecasted at a global and regional level.

New Digital Citizens Alliance Research Finds YouTube Fails to Stop Shady Operators Capitalizing on Coronavirus Fears

Alphabet Inc., Go software, Social media, Video hosting, YouTube, World Wide Web, Vaccine, Software, Digital media
Friday, April 3, 2020 - 3:27pm

Researchers found multiple examples of videos on YouTube offering medical masks and vaccines that sellers claim will protect buyers from the coronavirus.

Key Points: 
  • Researchers found multiple examples of videos on YouTube offering medical masks and vaccines that sellers claim will protect buyers from the coronavirus.
  • The research is published in a new report, " YouTube Enabling (Maybe Validating) Shadowy Sellers of Medical Masks and Bogus Vaccines ."
  • One seller who simply goes by "Real ID Card Fake Passport Producer" used YouTube to offer "Covid 19 Drugs."
  • Researchers were also concerned that YouTube is including a link to CDC information on these videos from shady operators.

Shareholder Alert: Robbins LLP Reminds Investors Inovio Pharmaceuticals, Inc. (INO) Sued for Misleading Shareholders

Legal, Professional services, Vaccination, Vaccine, Virology
Thursday, April 2, 2020 - 7:16pm

Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 14, 2020 and March 9, 2020.

Key Points: 
  • Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 14, 2020 and March 9, 2020.
  • Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.
  • If you suffered a loss as a result of Inovio's misconduct, click here .
  • Consequently, Inovio admitted the Company had not developed a COVID-19 vaccine but rather a "vaccine construct."

UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine

General Health, Infectious diseases, Health, Pharmaceutical, Clinical trials, Viruses, Medicine, Medical specialties, Vaccination, Influenza vaccines, Vaccines, Flu pandemic, Severe acute respiratory syndrome-related coronavirus, Vaccine, Severe acute respiratory syndrome, Influenza A virus subtype H1N1, Sinovac Biotech
Thursday, April 2, 2020 - 5:15pm

Kawaokas lab will insert gene sequences from SARS-CoV-2, the novel coronavirus that causes the disease COVID-19, into M2SR so that the new vaccine will also induce immunity against the coronavirus.

Key Points: 
  • Kawaokas lab will insert gene sequences from SARS-CoV-2, the novel coronavirus that causes the disease COVID-19, into M2SR so that the new vaccine will also induce immunity against the coronavirus.
  • Bharat Biotech in Hyderabad, India will then begin production scale-up for safety and efficacy testing in humans.
  • Bharat Biotech has commercialized 16 vaccines, including a vaccine developed against the H1N1 flu that caused the 2009 pandemic.
  • Bharat Biotech will manufacture the vaccine, conduct clinical trials and prepare to produce the vaccine for global distribution.

Cancer Vaccine Start Up, Calviri, Closes Successful Seed Funding Round

Biotechnology, Pharmaceutical, Health, Oncology, Finance, Money, Economy, Arizona State University, The Biodesign Institute, Angel investor, Seed money, Vaccine
Thursday, April 2, 2020 - 5:37pm

Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on ending deaths from cancer, today announced the closing of $2.25 million in seed round funding.

Key Points: 
  • Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on ending deaths from cancer, today announced the closing of $2.25 million in seed round funding.
  • The funding is from five private investors including Dr. Jacque Sokolov, a Calviri Board member, and Dr. Mitzi Krockover.
  • This process is the basis for the design of off-the-shelf vaccines for any cancer, as well as diagnostics for the early detection of any cancer.
  • Kathryn Sykes, VP of Research and Product Development, stated, We will use the funding to demonstrate the strengths of this unique technology.